vorinostat has been researched along with Acute Disease in 15 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 9.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 7.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Vorinostat is an inhibitor of histone deacetylases and was shown to attenuate GVHD in preclinical models." | 6.79 | Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. ( Beumer, JH; Braun, T; Chang, L; Choi, SW; Couriel, DR; Dinarello, CA; DiPersio, JF; Ferrara, JL; Goldstein, S; Hou, G; Kitko, C; Krijanovski, OI; Lehmann, MH; Levine, JE; Magenau, JM; Mapara, MY; Paczesny, S; Pawarode, A; Reddy, P; Stockerl-Goldstein, K; Sun, Y; Tawara, I; Yanik, GA, 2014) |
| "The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT)." | 5.24 | Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. ( Braun, T; Choi, SW; Dinarello, CA; Gatza, E; Henig, I; Magenau, J; Parkin, B; Pawarode, A; Reddy, P; Riwes, M; Yanik, G, 2017) |
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 5.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 3.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Vorinostat is an inhibitor of histone deacetylases and was shown to attenuate GVHD in preclinical models." | 2.79 | Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. ( Beumer, JH; Braun, T; Chang, L; Choi, SW; Couriel, DR; Dinarello, CA; DiPersio, JF; Ferrara, JL; Goldstein, S; Hou, G; Kitko, C; Krijanovski, OI; Lehmann, MH; Levine, JE; Magenau, JM; Mapara, MY; Paczesny, S; Pawarode, A; Reddy, P; Stockerl-Goldstein, K; Sun, Y; Tawara, I; Yanik, GA, 2014) |
| " HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro." | 2.75 | A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. ( Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010) |
| " Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given after vorinostat." | 1.35 | Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. ( Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tong, J | 1 |
| Zhou, J | 1 |
| Fang, M | 1 |
| Wang, G | 1 |
| Fu, S | 1 |
| Sun, B | 1 |
| Lv, J | 1 |
| Alatrash, G | 1 |
| Saberian, C | 1 |
| Bassett, R | 1 |
| Thall, PF | 1 |
| Ledesma, C | 1 |
| Lu, Y | 1 |
| Daher, M | 1 |
| Valdez, BC | 1 |
| Kawedia, J | 1 |
| Popat, U | 1 |
| Mehta, R | 1 |
| Oran, B | 1 |
| Nieto, Y | 1 |
| Olson, A | 1 |
| Anderlini, P | 1 |
| Marin, D | 1 |
| Hosing, C | 1 |
| Alousi, AM | 1 |
| Shpall, EJ | 1 |
| Rondon, G | 1 |
| Chen, J | 1 |
| Qazilbash, M | 1 |
| Champlin, RE | 1 |
| Kebriaei, P | 1 |
| Zierfuss, B | 1 |
| Weinhofer, I | 1 |
| Kühl, JS | 1 |
| Köhler, W | 1 |
| Bley, A | 1 |
| Zauner, K | 1 |
| Binder, J | 1 |
| Martinović, K | 1 |
| Seiser, C | 1 |
| Hertzberg, C | 1 |
| Kemp, S | 1 |
| Egger, G | 1 |
| Leitner, G | 1 |
| Bauer, J | 1 |
| Wiesinger, C | 1 |
| Kunze, M | 1 |
| Forss-Petter, S | 1 |
| Berger, J | 1 |
| Choi, SW | 2 |
| Braun, T | 2 |
| Henig, I | 1 |
| Gatza, E | 1 |
| Magenau, J | 1 |
| Parkin, B | 1 |
| Pawarode, A | 2 |
| Riwes, M | 1 |
| Yanik, G | 1 |
| Dinarello, CA | 2 |
| Reddy, P | 2 |
| Mussai, F | 1 |
| Wheat, R | 1 |
| Sarrou, E | 1 |
| Booth, S | 1 |
| Stavrou, V | 1 |
| Fultang, L | 1 |
| Perry, T | 1 |
| Kearns, P | 1 |
| Cheng, P | 1 |
| Keeshan, K | 1 |
| Craddock, C | 2 |
| De Santo, C | 1 |
| Holkova, B | 1 |
| Supko, JG | 1 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| Shapiro, GI | 1 |
| Perkins, EB | 1 |
| Ramakrishnan, V | 1 |
| Tombes, MB | 1 |
| Honeycutt, C | 1 |
| McGovern, RM | 1 |
| Kmieciak, M | 1 |
| Shrader, E | 1 |
| Wellons, MD | 1 |
| Sankala, H | 1 |
| Doyle, A | 1 |
| Wright, J | 1 |
| Roberts, JD | 1 |
| Grant, S | 1 |
| McNeil, C | 1 |
| Chang, L | 1 |
| Ferrara, JL | 1 |
| Magenau, JM | 1 |
| Hou, G | 1 |
| Beumer, JH | 1 |
| Levine, JE | 1 |
| Goldstein, S | 1 |
| Couriel, DR | 1 |
| Stockerl-Goldstein, K | 1 |
| Krijanovski, OI | 1 |
| Kitko, C | 1 |
| Yanik, GA | 1 |
| Lehmann, MH | 1 |
| Tawara, I | 1 |
| Sun, Y | 1 |
| Paczesny, S | 1 |
| Mapara, MY | 1 |
| DiPersio, JF | 1 |
| Conte, M | 1 |
| Dell'Aversana, C | 1 |
| Benedetti, R | 1 |
| Petraglia, F | 1 |
| Carissimo, A | 1 |
| Petrizzi, VB | 1 |
| D'Arco, AM | 1 |
| Abbondanza, C | 1 |
| Nebbioso, A | 1 |
| Altucci, L | 1 |
| Shiozawa, K | 1 |
| Nakanishi, T | 1 |
| Tan, M | 1 |
| Fang, HB | 1 |
| Wang, WC | 1 |
| Edelman, MJ | 1 |
| Carlton, D | 1 |
| Gojo, I | 1 |
| Sausville, EA | 1 |
| Ross, DD | 1 |
| Hauswald, S | 1 |
| Duque-Afonso, J | 1 |
| Wagner, MM | 1 |
| Schertl, FM | 1 |
| Lübbert, M | 1 |
| Peschel, C | 1 |
| Keller, U | 1 |
| Licht, T | 1 |
| Kadia, TM | 1 |
| Yang, H | 1 |
| Ferrajoli, A | 1 |
| Maddipotti, S | 1 |
| Schroeder, C | 1 |
| Madden, TL | 1 |
| Holleran, JL | 1 |
| Egorin, MJ | 1 |
| Ravandi, F | 1 |
| Thomas, DA | 1 |
| Newsome, W | 1 |
| Sanchez-Gonzalez, B | 1 |
| Zwiebel, JA | 1 |
| Espinoza-Delgado, I | 1 |
| Kantarjian, HM | 1 |
| Garcia-Manero, G | 1 |
| Bradbury, CA | 1 |
| Khanim, FL | 1 |
| Hayden, R | 1 |
| Bunce, CM | 1 |
| White, DA | 1 |
| Drayson, MT | 1 |
| Turner, BM | 1 |
| Mahlknecht, U | 1 |
| Schönbein, C | 1 |
| Steinhoff, M | 1 |
| Beyer, M | 1 |
| Roewert-Huber, J | 1 |
| Lukowsky, A | 1 |
| Assaf, C | 1 |
| Sterry, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant[NCT01790568] | Phase 2 | 26 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy With Ustekinumab[NCT03167437] | Phase 1/Phase 2 | 35 participants (Anticipated) | Interventional | 2017-10-30 | Recruiting | ||
| Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant[NCT00810602] | Phase 1/Phase 2 | 61 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01790568)
Timeframe: 1 year
| Intervention | percentage of patients (Number) |
|---|---|
| Vorinostat | 16 |
Overall survival at 1 Year. (NCT01790568)
Timeframe: 1 Year
| Intervention | percentage of patients (Number) |
|---|---|
| Vorinostat | 76 |
"GVHD Staging:~Grade 2: (Skin) Maculopapular rash 25-50% BSA, (Liver) bilirubin 3.1-6mg/dl, (Gut) 1000-1500 ml/day for adult and 20-30ml/kg/day for child.~Grade 3: (Skin) Maculopapular rash >50% BSA, (Liver) 6.1-15mg/dl, (Gut) >1500mg/day for adult and >30ml/kg/day for child.~Grade 4: (Skin) Generalized erythroderma plus bullous formation and desquamation >5% BSA, (Liver) >15mg/dl, (Gut) Severe abdominal pain with or without ileus, or grossly bloody stool." (NCT01790568)
Timeframe: 100 Days
| Intervention | percentage of patients (Number) |
|---|---|
| Vorinostat | 22 |
Assess if the addition of Vorinostat to standard GVHD prophylaxis regimen can reduce the rate of grades 2-4 acute GVHD when compared to 48% in a cohort of identically treated RIC HSCT patients without vorinostat. A reduction of incidence to less than 25% will be considered successful. (NCT00810602)
Timeframe: 100 days
| Intervention | percentage of participants (Number) |
|---|---|
| Vorinostat Prophylaxis | 22 |
The safety and feasibility will be partially measured by the number of serious adverse events (SAE) recorded by participants receiving at least one dose of Vorinostat. (NCT00810602)
Timeframe: 100 days
| Intervention | Number of Serious Adverse Events (Number) |
|---|---|
| Vorinostat Prophylaxis | 33 |
Determine the cumulative incidence of relapse at 2 years. (NCT00810602)
Timeframe: two years
| Intervention | percentage of participants (Number) |
|---|---|
| Vorinostat Prophylaxis | 16 |
To determine 2-year overall survival rate (NCT00810602)
Timeframe: two years
| Intervention | percentage of subjects (Number) |
|---|---|
| Vorinostat Prophylaxis | 73 |
6 trials available for vorinostat and Acute Disease
| Article | Year |
|---|---|
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti | 2022 |
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
Topics: Acetylation; Acute Disease; Adolescent; Adult; Aged; Demography; Feasibility Studies; Female; Graft | 2017 |
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginin | 2019 |
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo | 2013 |
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Topics: Acute Disease; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2014 |
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Topics: Acute Disease; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2014 |
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Topics: Acute Disease; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2014 |
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Topics: Acute Disease; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2014 |
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combi | 2010 |
9 other studies available for vorinostat and Acute Disease
| Article | Year |
|---|---|
The anti-inflammatory mechanism of SAHA in acute pancreatitis through HDAC5/SLIT2/Akt/β-catenin axis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; beta Catenin; Histone Deacetylases; Inflammation; | 2022 |
Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.
Topics: Acute Disease; Adrenoleukodystrophy; ATP Binding Cassette Transporter, Subfamily D; ATP Binding Cass | 2020 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Tri | 2013 |
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
Topics: Acute Disease; Aged; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Female; Ge | 2015 |
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabi | 2009 |
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Biological Trans | 2009 |
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
Topics: Acetylation; Acute Disease; Adult; Antigens, CD34; Butyrates; DNA Methylation; Enzyme Inhibitors; Ge | 2005 |
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Topics: Acute Disease; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; D | 2008 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fev | 2008 |